title: Patient satisfaction with a pressurized metered-dose inhaler with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination.
abstract: BACKGROUND
  Inhaled delivery devices that are easy to use and facilitate dose tracking may lead to improved patient satisfaction and adherence. Patient satisfaction with a metered-dose inhaler (MDI) with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination (MF/F MDI dose counter) was evaluated in subjects with persistent asthma or chronic obstructive pulmonary disease.
  
  
  METHODS
  In this multicenter study (N = 272, age range: 12-92 years), subject experience and satisfaction with MDI devices was evaluated using baseline and poststudy surveys. Subjects responded to the baseline survey based on their previous MDI experience, then received MF/F MDI 100/10 μg with the integrated dose counter for 4 weeks before completing the poststudy survey. This evaluation was part of a broader study objective to assess performance of the MF/F MDI dose counter.
  
  
  RESULTS
  At baseline, 52% of subjects reported being extremely satisfied with their previous MDI. After using the MF/F MDI dose counter, a relative increase of 43% in overall satisfaction was observed. Approximately 90% of subjects agreed the MF/F dose counter helped them track doses and was easy to use; >80% agreed the inhaler was of good quality and well designed. Subjects agreed the dose counter relieved anxiety about running out of medication (68%) or taking a subtherapeutic dose (65%). Nearly 80% of subjects had no reservations about the MF/F MDI dose counter, and most subjects stated they would request it from their physician (66%) and recommend it to a friend (75%).
  
  
  CONCLUSIONS
  The MF/F MDI dose counter was found to be easy to use and have overall high patient satisfaction.
authors: Department of Pediatrics, University of North Carolina School of Medicine, North Carolina Clinical Research, Raleigh, NC, USA. claforce@nccr.com
authors: Craig
authors: C
authors: LaForce
authors: Cindy
authors: C
authors: Weinstein
authors: Robert A
authors: RA
authors: Nathan
authors: Steven F
authors: SF
authors: Weinstein
authors: Heribert
authors: H
authors: Staudinger
authors: Eli O
authors: EO
authors: Meltzer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D032882:Comprehension; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006804:Ergonomics / Q000706:statistics & numerical data; D004983:Ethanolamines / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D000068759:Formoterol Fumarate; D006801:Humans; D008297:Male; D036501:Metered Dose Inhalers; D008875:Middle Aged; D000068656:Mometasone Furoate; D000068758:Mometasone Furoate, Formoterol Fumarate Drug Combination; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D011244:Pregnadienediols / Q000008:administration & dosage* / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D004983:Ethanolamines; D000068758:Mometasone Furoate, Formoterol Fumarate Drug Combination; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D000068759:Formoterol Fumarate